Objectives: Chloramphenicol is an old broad-spectrum antibiotic. We assessed its efficacy and safety.
Introduction
In recent years the rise in MDR bacteria has outpaced the development of new, effective antibiotics. This has led to a re-examination of antimicrobial agents that were abandoned in the past. 1, 2 Chloramphenicol is an old antimicrobial agent that is rarely used today. In the past it was in common use due to its broad spectrum of activity against many Gram-positive and Gram-negative bacteria. Its mechanism of action is generally bacteriostatic, although it may be bactericidal in high concentrations or when used against Streptococcus pneumoniae, Neisseria meningitidis or Haemophilus influenzae. Chloramphenicol is effective parenterally as well as orally 3 (with a bioavailability of 80%) and has excellent tissue penetration. It achieves 30%-50% of the serum concentration in the CSF and therapeutic levels are also achieved in pleural, ascitic and synovial fluids. It is metabolized primarily in the liver and is excreted by the kidneys in an inactive form. 4 Therefore dose adjustment is required in cases of hepatic insufficiency but not with renal insufficiency.
Until 1980, chloramphenicol, ampicillin and co-trimoxazole were the drugs of choice to treat typhoid. Since then, the increasing incidence of strains resistant to chloramphenicol, ampicillin and co-trimoxazole has led to the use of fluoroquinolones, particularly ciprofloxacin, for the empirical treatment of enteric fever. 5 Resistance to fluoroquinolones quickly emerged, as has been reported in South Asia and elsewhere since the early 1990s. 6, 7 A recently published meta-analysis showed sharply increasing trends in resistance to nalidixic acid and ciprofloxacin for both Salmonella enterica serotype Typhi and S. enterica serotype Paratyphi A in Nepal (with a pooled prevalence in 2011 of ciprofloxacin resistance of 14.3%, 95% CI 5.2 -26.9), while resistance to traditional first-line antibiotics such as chloramphenicol and co-trimoxazole has significantly decreased for both organisms (the pooled prevalence for the same time period was 2.0%, 95% CI 1.1-3.2). 8 The most significant adverse effect of chloramphenicol is bone marrow suppression. This may occur by two distinct mechanisms: dose-related bone marrow suppression, which usually occurs after more than 7 days of treatment, and fatal irreversible idiosyncratic aplastic anaemia. 9 The latter is rare, affecting 1 in approximately 30 000 or more courses of therapy with oral chloramphenicol and cannot be predicted. 10 In light of these data we conducted a systematic review and meta-analysis of all randomized controlled trials (RCTs) assessing chloramphenicol in the treatment of different infections. We aimed to assess the efficacy and safety of chloramphenicol in its classical indications-respiratory infections, Salmonella infections and meningitis-and also to ascertain whether it had been tested in hospitalized patients in the context of drug-resistant pathogens (such as VRE, MRSA or MDR Gram-negative bacteria).
Methods

Inclusion criteria
We included all randomized or pseudo-randomized (using alternation, patient identification number or other non-truly random methods of randomization) controlled clinical trials that assessed hospitalized and community patients, of any age, with systemic bacterial infections that can cause sepsis. We included studies comparing chloramphenicol as monotherapy versus any other antibiotic regimen. We excluded trials that employed antibiotics no longer in human use and trials in which more than 50% bacterial resistance to one of the studied drugs was found, unless the study presented outcome data on the patients with susceptible bacteria. We also excluded trials using chloramphenicol derivate antibiotics. When studies included more than one comparison with chloramphenicol, every arm was counted independently by its comparator antibiotic group; therefore some chloramphenicol study arms were counted twice (n¼4).
Primary outcome
The primary outcome assessed was overall mortality at the end of treatment (EOT) and at the end of follow-up (EOF). The secondary outcomes included treatment failure as defined in each study. (We accepted the study definitions for treatment failure or calculated it as 1 -treatment success, as defined in the studies. Whenever possible, we included all deaths as failures.) Other secondary outcomes included neurological sequelae in studies on meningitis, microbiological failure or persistence as defined by the individual trials, a relapse of the primary infection (mainly in typhoid fever), the long-term carriage of or colonization with Salmonella sp. in typhoid fever, the development of resistance at EOF, the duration of hospital stay (comprising the need for hospitalization in studies conducted in the community), the number of readmissions, the duration of fever, the duration of treatment and the adverse events. Adverse events are shown for each infection separately and then for all trials together.
Search strategy and selection criteria
We conducted a comprehensive search in an attempt to identify all the relevant studies regardless of language, publication status or year of The risk of bias assessment and selective outcome reporting were determined using criteria suggested in the Cochrane handbook, 11 and the effect of risk of bias was assessed through sensitivity analyses. We assessed the methodological quality according to generation of allocation, allocation concealment, blinding, intention-to-treat analysis and the number of patients excluded from the outcome assessment. Allocation concealment and generation were graded as adequate (A), unclear (B), inadequate (C) or not used (D) using the criteria suggested in the Cochrane handbook, and the effect of risk of bias on results was examined through sensitivity analyses.
Statistical analysis
Risk ratios (RRs) for dichotomous data and weighted mean differences for continuous outcomes (length of hospitalization) were calculated for individual trials, with 95% CI. An RR .1 favours antibiotics other than chloramphenicol. Heterogeneity in the results of the trials was assessed using the I 2 measure of inconsistency. When I 2 was ≤30% we used a fixedeffect (FE) model; otherwise a random-effect (RE) model was used. 11 We expected that heterogeneity might originate from the type of infection, including meningitis, enteric fever and respiratory tract infections (lower and upper), the type of comparator antibiotic (quinolone, b-lactam or other), whether the patient was an outpatient or hospitalized and the different age groups (children or adults). Analyses were stratified by type of infection. We attempted to extract outcome data for other subgroups. A funnel plot for the primary outcome measured was visually examined for assessing the reporting bias.
Results
The trial flow chart is shown in Figure 1 . Sixty-six RCTs, conducted from 1964 through 2011, were included in the review (Table 1 ). All but one were published in journals, and one was published as a meeting abstract. Five trials assessed chloramphenicol for The first letter is a grade for the quality of allocation generation and the second letter is a grade for the quality of allocation concealment (both are graded A for adequate, B for unclear or unknown methods and C for inadequate).
Systematic review respiratory tract infections, 12 -16 5 for meningitis, 17 -21 55 trials for enteric fever 22 -76 and 1 for Mediterranean spotted fever. 77 For respiratory tract infections and meningitis, all comparisons but one in each group were with b-lactams. For enteric fever, chloramphenicol was compared with fluoroquinolones in 10 trials, with penicillins in 13, with cephalosporin in 11, with trimethoprim/sulfamethoxazole in 15 and with other antibiotics (mainly furazolidone) in 10. The trials included 9711 patients, 2487 in the respiratory tract infection trials, 1753 in the meningitis trials, 5403 in the typhoid trials and 68 in the Mediterranean spotted fever trial. In the latter, Table 2 .
Respiratory tract infections
Five trials assessed chloramphenicol for respiratory tract infections, 12 -16 including 2487 patients, from the years 1972 until 2008. Two included only children and assessed severe pneumonia, and three included only adults and assessed exacerbations of bronchitis. Three trials compared chloramphenicol with penicillins, one with a cephalosporin and one with tetracycline. Three trials were from Europe, one was from Papua New Guinea and one took place in eight tertiary care hospitals in Bangladesh, Ecuador, India, Mexico, Pakistan, Yemen, and Zambia. None was sponsored by drug companies. Concerning the methodology, all studies but one had adequate allocation concealment, three were open and in two only the outcome assessor was blinded. In three of the five studies, baseline resistance (prior to antibiotic therapy) was given, with no significant difference between the study arms.
Mortality at EOF
Mortality at EOF was reported in two out of the five trials. These trials included only children and compared chloramphenicol with penicillins in severe pneumonia. EOF was defined up to 6 weeks. There was significantly higher mortality in the chloramphenicol arm (RR 1.40, 95% CI 1.00 -1.97), with no heterogeneity (I 2 ¼0%) ( Figure 2 ).
Failure at EOF/EOT
Failure at EOF/EOT was reported in all five trials-in two at EOF and in three at EOT. Pooling all the data, there was no significant difference between the treatment arms (RR 1.05, 95% CI 0.80 -1.38), with substantial heterogeneity (I 2 ¼ 60%) (Figure 3 ). Heterogeneity was reduced (I 2 ¼ 27%) when evaluating studies including only adults (RR 0.80, 95% CI 0.55 -1.18), which are also the same studies that gave data to failure at EOT only. 
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Adverse events
Adverse events were reported in three of the five studies. The rate of adverse events rate was significantly lower in the chloramphenicol arm (RR 0.43, 95% CI 0.28 -0.66), with no heterogeneity (I 2 ¼ 0%). Of these, the two trials for which detailed side effects were given included adults with up to 6 weeks of follow-up and compared chloramphenicol with ampicillin or tetracycline. 14, 15 Side effects were more frequent in the control group and included more nausea and vomiting, rash and diarrhoea. In the chloramphenicol arm, there was a higher rate of anaemia and leucopenia, which was not statistically or clinically significant (reported in two studies only).
Meningitis
Five trials, including 1753 patients, assessed chloramphenicol for meningitis 17 -21 from 1972 to 2005. All the trials included only children. All but one trial compared chloramphenicol with b-lactams (two with penicillins and two with a cephalosporin) and one compared it with tetracycline. Three trials were from Nigeria, one trial was from Finland and one was from the USA. Two trials were sponsored by Médecins Sans Frontières (MSF). In relation to the methodology, most of the studies did not report allocation concealment and one reported adequate methodology. All were open. Data on baseline resistance (prior to antibiotic therapy) were given in only one of the five studies, with no significant difference between the study arms. Adverse events were reported in all the studies (in one study only data for the chloramphenicol arm were reported 17 ) . No adverse events were noted in both arms in all studies. Only two trials reported haematological side effects, again with none occurring in both arms.
Mortality at EOF
Mortality at EOF was reported in three out of the five trials. EOF was defined only in two trials and was up to 12 months. There was a borderline significant difference in mortality that was higher in the chloramphenicol arm (RR 1.27, 95% CI 1.00 -1.60), with no heterogeneity (I 2 ¼0%). When adding the two additional studies that reported mortality at EOT, the results did not change substantially (RR 1.20, 95% CI 0.96 -1.50), with no heterogeneity (Figure 4 ).
Failure at EOF
Failure at EOF was reported in four of the five trials. There was no significant difference between the treatment arms (RR 1.26, 95% CI 0.76 -2.07), with substantial heterogeneity (I 2 ¼ 64%) ( Figure 5 ). Heterogeneity was substantially reduced (I 2 ¼ 0%) when excluding one trial from Finland that compared four arms (chloramphenicol, chloramphenicol with ampicillin, cefotaxime and ceftriaxone) for the treatment of bacterial meningitis and showed extreme results in favour of the comparator arms. 19 This was also the only study with reliable methodology (adequate allocation concealment or double-blind only).
Enteric fever
Fifty-five trials, including 5403 patients, assessed chloramphenicol for typhoid/enteric fever 22 -76 from 1964 until 2011. Seven trials included only adults, whereas all the rest included children or exclusively studied only children. Of the studies, 24 compared chloramphenicol with b-lactams (13 with penicillins, 11 with cephalosporins), 10 compared chloramphenicol with a fluoroquinolone, 15 chloramphenicol with trimethoprim/sulfamethoxazole, 8 chloramphenicol with furazolidone and 1 chloramphenicol with azithromycin (three studies were counted twice, one had two arms comparing chloramphenicol with a penicillin and trimethoprim/sulfamethoxazole and two compared it with trimethoprim/ sulfamethoxazole and furazolidone). Most studies were from developing countries (India, Philippines, Nepal, Indonesia). Thirty-one studies were sponsored by pharmaceutical companies marketing the comparator drug. In terms of the methodology, most had unclear allocation concealment methods (46 studies), five reported inadequate methodology (using pseudo-randomization) and five were adequate. Six were double-blind studies, and the rest for which information existed were open studies. In 29 studies, baseline resistance (prior to antibiotic therapy) was given, with no significant difference between the study arms (RR 1.34, 95% CI 0.87-2.07), no heterogeneity (I 2 ¼ 0%).
Mortality at EOF
Mortality at EOF was reported in 17 trials, which included 1287 patients. EOF was defined from weeks up to 12 months. There was no significant difference between the treatment arms (RR 1.30, 95% CI 0.73 -2.29), with no heterogeneity (I 2 ¼ 0%). A sensitivity analysis of the type of antibiotic assessed (quinolone, b-lactam or trimethoprim/sulfamethoxazole) compared with chloramphenicol revealed no difference between the treatment arms in all comparisons ( Figure 6 ). A subgroup analysis of studies including only adults also showed that there was no significant difference between the treatment arms (RR 1.42, 95% CI 0.57 -3.49), with no heterogeneity (I 2 ¼ 0%). When including only studies with reliable methodology (adequate allocation concealment or double-blind studies only), there was no difference in effect (RR 1.53, 95% CI 0.34 -6.87, I
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Failure at EOF
Failure at EOF was reported in 31 of 57 trials, including 2578 patients. There were significantly more failures with chloramphenicol (RR 1.44, 95% CI 1.07 -1.93), with no heterogeneity (I 2 ¼ 0%). Assessing studies that included only adults, there was greater failure with chloramphenicol but the difference did not reach statistical significance (RR 1.66, 95% CI 0.96 -2.86) and there was no heterogeneity. A subgroup analysis of the type of antibiotic assessed (quinolone, b-lactam or trimethoprim/sulfamethoxazole) compared with chloramphenicol revealed that this difference derived mainly from studies comparing it with a fluoroquinolone (RR 1.85, 95% CI 1.07 -3.20, more failure with chloramphenicol, no heterogeneity) (Figure 8) . When including only studies with a reliable methodology (adequate allocation concealment or double-blind studies only), the difference did not reach statistical significance (RR 1.33, 95% CI 0.79 -2.25, I 2 ¼ 41%) but only four studies of high quality were found. The funnel plot for this outcome was symmetrical ( Figure 9 ).
Adverse events
The occurrence of any adverse event was reported in 35 studies including 3745 patients. There was no difference between the two arms (RR 0.89, 95% CI 0.70 -1.14) but there was considerable heterogeneity (I 2 ¼ 50%). In a subgroup analysis of the type of comparator (quinolone, b-lactam or trimethoprim/sulfamethoxazole), there was no significant difference between chloramphenicol and each antibiotic class (Figure 10 ). The heterogeneity derived mainly from the comparison with fluoroquinolones, with a heterogeneity of 61%. This comparison, the study by Arjyal et al., 49 which compared chloramphenicol with gatifloxacin, demonstrated considerably greater adverse effects with chloramphenicol, especially diarrhoea and nausea. When this study was excluded from the analysis, the heterogeneity dropped to 0% in the comparison with fluoroquinolones, and to 28% in the total comparison.
Sixteen studies described anaemia as a side effect. These included 1436 patients, and 11 studies reported no cases of anaemia. Pooling the studies showed significantly higher rates of anaemia in the chloramphenicol arm (RR 2.54, 95% CI 1.42 -4.53), with no heterogeneity. Nineteen studies gave neutropenia as a side effect. These included 2372 patients, and 14 studies reported no cases of neutropenia. Pooling the studies showed that there was no significant difference between the study groups (RR 1.26, 95% CI 0.79-2.00), with no heterogeneity.
Adverse events in all trials
The occurrence of any adverse event was reported in 43 studies including 6274 patients. There was no difference between the two arms (RR 0.80, 95% CI 0.62-1.02), although there was considerable heterogeneity (I 2 ¼ 56%). The heterogeneity derived mainly from the comparison with fluoroquinolones. Twenty studies (including 2072 patients) reported anaemia, the figure being significantly higher in the chloramphenicol arm (RR 2.80, 95% CI 1.65-4.75), with no heterogeneity. The number-needed-to-harm was 33. Twenty-three studies (including 3008 patients) reported neutropenia. There was no difference between the two arms (RR 1.36, 95% CI 0.88 -2.11), with no heterogeneity. The numberneeded-to-harm was 100. A cutaneous rash was reported in 26 studies but its frequency did not differ between the two arms (RR 0.85 95% CI 0.57 -1.26). By contrast, gastrointestinal side effects (including nausea, vomiting and diarrhoea) were reported in 27 studies (3293 patients) and were significantly more common in the comparator arm (RR 0.67, 95% CI 0.46 -0.99). The number-needed -to-treat was 20. See Figures S1 -S4 (available as Supplementary data at JAC Online).
Discussion
Examining RCTs comparing chloramphenicol as monotherapy versus any other antibiotic regimen for respiratory tract infections, meningitis and enteric fever, we found significantly higher mortality in the chloramphenicol arm for respiratory tract infections (RR 1.4, 95% CI 1.00 -1.97, I
2 ¼0%) and meningitis (RR 1.27, 95% CI 1.00 -1.60, I
2 ¼ 0%).The point estimate was similar for enteric fever but the difference did not reach statistical significance (RR 1.31, 95% CI 0.74 -2.31, I
2 ¼ 0%). No statistically significant difference was found between chloramphenicol and other antibiotics regarding failure at EOF, except for enteric fever, for which there were significantly more failures with chloramphenicol compared with other antibiotics (RR 1.46, 95% CI 1.07 -2.00, I
2 ¼ 0%). A subgroup analysis showed that this difference derived mainly from studies comparing chloramphenicol with fluoroquinolones (RR 1.85, 95% CI 1.07-3.2, I 2 ¼0%). Regarding adverse events, there was no statistically significant difference between chloramphenicol and other antibiotics except for anaemia, which was reported in 20 studies (2072 patients) and was significantly more common in the chloramphenicol arm (RR 2.80, 95% CI 1.65 -4.75, I
2 ¼ 0%). In contrast, gastrointestinal side effects (including nausea, vomiting and diarrhoea), which were reported in 27 studies (3293 patients), were significantly more common in the comparator arm (RR 0.67, 95% CI 0.46-0.99). 78 recommended that, in epidemics of meningococcus, in children above 2 years old and adults, a single dose of ceftriaxone or a single dose of oily chloramphenicol should be given as a presumptive treatment. We showed that chloramphenicol treatment in this subgroup of patients is associated with higher rates of death.
WHO guidelines from 2003 for the diagnosis, treatment and prevention of typhoid fever state that although multidrug resistance is rising, chloramphenicol is still widely prescribed in developing countries for the treatment of typhoid fever. Salmonella Typhi strains from many areas of the world, e.g. most countries in Africa and Asia, remain susceptible to this drug. These guidelines conclude that evidence suggests fluoroquinolones are the optimal choice for the treatment of typhoid fever in adults and that they may also be used in children. 79 In areas of the world where the fluoroquinolones are not available or are not registered for public health use and where the bacterium is still fully susceptible to traditional first-line drugs (chloramphenicol, amoxicillin or trimethoprim/sulfamethoxazole), these remain appropriate for the treatment of typhoid fever.
Chloramphenicol may be a useful antimicrobial agent for MDR organisms such as VRE, MRSA or MDR Gram-negative bacteria. Data from 25 university hospitals in Europe between 1997 and 1999, representing a total of 3051 MSSA and MRSA isolates, showed that 96% of MSSA and 83% of MRSA isolates were susceptible to chloramphenicol. 80 Data published from another tertiary centre in Israel during 2010 showed that of 413 Enterobacteriaceae isolates, 182 (44.1%) were resistant to amoxicillin/clavulanate but only 76 (18.4%) were resistant to chloramphenicol. 81 In a study of 78 episodes of VRE bacteraemia, 51 patients (65.4%) received chloramphenicol. Chloramphenicol treatment led to a favourable clinical (61.1%) and microbiological (79.1%) response, with an insignificantly lower mortality rate than with other antibiotics (rifampicin, penicillin, ampicillin or ciprofloxacin). 82 In a study from Mount Sinai Hospital, chloramphenicol was used as a treatment for nosocomial VRE infections in 16 liver transplant recipients; 93% of the VRE isolates were susceptible to chloramphenicol and resistance did not occur in recurrent VRE isolates. There were no haematological adverse effects. 83 On the other hand, a study from the UK checking the activity of chloramphenicol and other antibiotics against 81 carbapenemresistant Enterobacteriaceae isolates demonstrated that chloramphenicol, ciprofloxacin and nitrofurantoin inhibited ,25% of the isolates at the breakpoint, whereas colistin was active against 75/81 isolates (92.6%). 84 We found no RCTs that addressed these infections or used chloramphenicol as an empirical treatment for hospital-acquired infections.
We acknowledge several limitations of our study. A major limitation is the current progressive change in the antibiotic susceptibility pattern. The studies included are old (1964 through 2008). Nevertheless, in most studies included in our analysis, baseline resistance (prior to antibiotic therapy) was given, with no significant difference between the two study arms compared; therefore the efficacy of chloramphenicol versus other antibiotic therapy was actually assessed. The results are relevant to bacteria susceptible to chloramphenicol. The duration of follow-up differed between the studies. The time frame of an RCT might not be suitable for examining rare and long-term haematological side effects. In the subgroup of patients with respiratory tract infections, studies on pneumonia included only children, and studies with adults included only exacerbations of bronchitis, so it is difficult to draw conclusions relating to pneumonia in adults. Regarding the methodology, most studies had unclear allocation concealment methods and were open. Finally, many of the studies included were sponsored by pharmaceutical companies marketing the comparator drug to chloramphenicol, and this might have influenced the results. Other studies might not have been published because of negative or inconclusive results, especially in the era during which these studies were performed. This could lead to erroneous conclusions showing a disadvantage with chloramphenicol.
Chloramphenicol cannot be recommended as a first-line choice for treating respiratory tract infections, meningitis or enteric fever in areas of the world where alternative antibiotics are available as these alternatives are probably more effective. Chloramphenicol is as safe as treatment alternatives for short antibiotic courses. Regarding MDR organisms such as VRE, MRSA and MDR Gram-negative bacteria, we did not find RCTs assessing the question of whether chloramphenicol might be a useful antimicrobial agent, and from the studies available it is hard to conclude its place in treating these infections. RCTs are needed to test chloramphenicol treatment against these organisms when better alternatives do not exist.
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